In Silico Inhibition of Three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal ‘Immunoablative’ Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough.
Research Square (Research Square)